<DOC>
	<DOCNO>NCT01483898</DOCNO>
	<brief_summary>This study design evaluate efficacy safety ixmyelocel-T , patient-specific expand multicellular therapy , treatment patient critical limb ischemia ( CLI ) . The study randomize , vehicle control ( placebo ) study CLI patient option revascularization procedure . All patient randomize undergo small volume bone marrow aspiration 15-minute outpatient in-office procedure . All patient receive injection either ixmyelocel-T vehicle-control pre-identified index leg . Patients follow 18 month .</brief_summary>
	<brief_title>An Efficacy Safety Study Ixmyelocel-T Patients With Critical Limb Ischemia ( CLI )</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<criteria>Males nonpregnant , nonlactating female Ages 35 90 year age Diagnosis CLI tissue loss ( correspond Rutherford Category 5 ; see Appendix B ) ulcer size least 0.5 cm2 , small sized ulcer penetrate subcutaneous tissue , and/or gangrene ( dry ) . In addition , subject must ONE follow document screening : Ankle systolic pressure &lt; 70 mm Hg Toe systolic pressure &lt; 50 mm Hg TcPO2 &lt; 30 mm Hg ( supine position ) Subjects must reasonable standardofcare option surgical endovascular revascularization intervention Subjects must follow : A narrative documenting reason site vascular specialist considers subject `` option '' . A vascular specialist principal investigator ( PI ) subinvestigator define : vascular surgeon , interventional cardiologist , certify vascular medicine specialist , interventional radiologist ; AND Secondary confirmation independent Eligibility Review Committee ( ERC ; see Section 8.1 ) review appropriate document include , limited : imaging result , medical record , surgical history , site vascular specialist narrative documenting reason `` option , '' and/or lab report . Major amputation index leg death anticipate within 3 month screen opinion vascular specialist ( must PI subinvestigator ) In opinion investigator , subject control medical therapy indicate CLI ( unless document contraindication intolerance ) Subject current ageappropriate American Cancer Society ( ACS ) similar ( e.g. , United States Preventative Service Task Force ) screen guideline Given medical history concurrent medication , subject acceptable candidate bone marrow aspiration intramuscular injection procedure opinion Investigator Subject willing able comply schedule visit , aspiration/injection procedure , wound care instruction treatment plan , study procedure duration study Provide personallysigned date informed consent document indicate subject ( legallyacceptable representative , permit site 's Investigational Review Board [ IRB ] ) inform pertinent aspect study Patients present follow randomize : Diseasespecific : Failed open surgical revascularization ( index leg ) within 4 week screen Visit 1 Acute limbthreatening ischemia , trauma , know nonatherosclerotic vascular disease ( e.g. , temporal/giant cell arteritis , Takayasu 's arteritis , Raynaud 's occlusive disease , Buerger 's disease ) , embolic disease , aortoiliac disease &gt; 50 % stenosis , history hypercoagulable state Advanced CLI ( i.e. , nonsalvageable ) define Rutherford Category 6 Clinical evidence invasive infection index leg ( e.g. , cellulitis , osteomyelitis , wet gangrene ) At screening , nonheel wound size &gt; 20 cm2 ( exclude toe gangrene ) ; wound heel &gt; 10 cm2 index leg measure Wound Core Lab ( WCL ) photograph ( and/or acetate ) provide site Previous amputation talus index leg Medical History Hemoglobin A1c ( HbA1c ) ≥ 10 % screen Diabetic subject uncontrolled untreated proliferative retinopathy determine dilate eye exam ( qualify eye care professional per American Diabetes Association guideline ) Blood clot disorder cause medication ( e.g. , thrombophilia ) Active nonbasal cell cutaneous malignancy require surgery , chemotherapy , and/or radiation past 12 month Current document drug alcohol abuse would interfere subject 's compliance study procedure Known allergy equine , porcine , bovine product Body mass index ( BMI ) ≥ 50 kg/m2 screen Established chronic kidney disease ( CKD ) require dialysis ( Stage 5 ) ; estimate creatinine clearance &lt; 15 mg/mL/min screen Systolic blood pressure ( SBP ) &gt; 200 mm Hg diastolic blood pressure ( DBP ) &gt; 120 mm Hg papilledema note via ophthalmoscope screen physical exam Within 3 month prior screen , clinically significant history cardiac disease Laboratory Parameters : Abnormal laboratory value ( performed central lab ) screening : Platelets &lt; 50,000 μL Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 3 time upper limit normal ( ULN ) Human immunodeficiency virus 1 ( HIV 1 ) , HIV 2 , syphilis positive ( rapid plasma reagin [ RPR ] ) Active hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) ; Exclusionary Procedures , Devices , Medication Exposure immunosuppressive therapy oncologic chronic nononcologic reason prior 12 month expect requirement course study ( e.g. , chemotherapy , radiation therapy , methotrexate ) Concurrent participation another clinical trial receive experimental medication within 30 day screen previously expose Aastrom 's ixmyelocel T product [ previously know tissue repair cell ( TRC ) , cardiac repair cell ( CRC ) , vascular repair cell ( VRC ) ] On index leg , use concomitant wound treatment currently approve ischemic woundhealing within 30 day prior screen plan initiate new , nonstandardofcare treatment index leg study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>critical limb ischemia</keyword>
	<keyword>REVIVE</keyword>
	<keyword>peripheral vascular disease</keyword>
	<keyword>CLI</keyword>
	<keyword>PAD</keyword>
	<keyword>MSC</keyword>
	<keyword>stem cell</keyword>
	<keyword>cell therapy</keyword>
</DOC>